1. Introduction {#sec1}
===============

It has been proposed that the C-reactive protein (CRP) has clinical utility as a biomarker in predicting risk of cardiovascular events \[[@B1]\] and a predictive value in the progression of type 2 diabetes (T2D) \[[@B2]\]. In obesity, there is an increase in the risk of coronary heart disease (CHD) by constant and progressive vascular damage, generated by a chronic low-grade inflammatory state \[[@B3]\]. It has been determined that adipocytes produce one-third of interleukin-6 (IL-6), the main stimulus for hepatic CRP production. Overweight or obese subjects have higher levels of this protein \[[@B4]\], which promotes the atherosclerotic process by increasing the expression of adhesion molecules (ICAM-1, VCAM-1), E-selectin, and the monocyte chemotactic protein-1 (MCP-1) in the endothelium \[[@B5]\]. CRP is also involved in decreased expression and mRNA half-life of endothelial nitric oxide synthase and activation of nuclear factor kappa B (NF*κ*B) that is involved in the transcription of numerous genes related with the inflammatory process \[[@B5]\]. It has also been involved in the modulation of angiogenesis and atherosclerotic, plaque instability by activating the signaling pathway of phosphatidylinositol-3 kinase (PI3 K) and extracellular signal-regulated kinases 1 and 2 (ERK 1/2) \[[@B6]\].

Obesity, age, gender, and diabetes are important factors that influence variation in blood levels of CRP. Also, there is a strong evidence of the genetic component in the variation of this protein, with heritability estimates of 35--40% \[[@B7]\]. Several studies have reported an association between single-nucleotide polymorphisms (SNPs) in the *CRP* gene with variation in blood levels of CRP, or with CHD, diabetes, microangiopathic stroke, insulin resistance, metabolic syndrome, or hypertension \[[@B8]--[@B10]\]. In particular, polymorphisms in the *CRP*gene on chromosome 1 have consistently been associated with basal CRP levels in both men and women \[[@B9], [@B11]\] and with varying degrees of risk in the development of CHD \[[@B8]\], while polymorphisms within the *CRP*promoter have been associated with differential transcription of *CRP*in clinically stable patients \[[@B12]\]. However, other studies have not been able to identify an association between *CRP* genotypes and the risk of CHD \[[@B13], [@B14]\].

Several studies report an association between single-nucleotide polymorphisms (SNPs) in the CRP gene with variation in blood levels of CRP with cardiovascular disease (CVD) and other diseases such as diabetes, microangiopathic stroke, insulin resistance, metabolic syndrome, and hypertension \[[@B12]\]. On the other hand, in the Mexican population, few studies have shown a relationship between *CRP* gene variants with blood levels of the protein in obesity, diabetes, and cardiovascular risk. Our research was conducted to evaluate the association between genotype and haplotype frequencies of SNPs rs1130864, rs1205, rs2794521, and rs3093062 in the *CRP* gene with serum levels of CRP, in healthy, obese, T2D obese, and T2D without obesity, or with the risk score of CHD. Currently, Mexico has one of the highest obesity rates in the world; one-third of children in Mexico are now classified as either overweight or obese \[[@B15]\].

2. Subjects and Methods {#sec2}
=======================

2.1. Previously Diagnosed {#sec2.1}
-------------------------

### 2.1.1. Subjects {#sec2.1.1}

A total of 402 individuals, 30 years or older, male and female, normotensive, genetically unrelated, and with ancestry in the state of Guerrero, Mexico, were studied. Patients from the ISSSTE Hospital Clinic and Health Center of Chilpancingo, Guerrero were invited to participate in the study. Patients were classified into four groups: 130 healthy individuals not overweight (BMI \< 25 kg/m^2^), 93 previously diagnosed with T2D without obesity (BMI \< 25 kg/m^2^), 106 obese subjects (BMI \> 30 kg/m^2^), and 73 previously diagnosed with T2D and obesity (BMI \> 30 kg/m^2^). Smokers, alcohol consumers, those with a diagnosis of CHD, respiratory tract infection, digestive or urinary tract in the last 15 days, or treated with anti-inflammatory drugs, or pregnant women were excluded. Individuals that accepted to participate signed the informed consent form. The protocol was approved by the Ethics Committee of the University of Guerrero. Each participant answered a questionnaire to obtain sociodemographic, family history, and history of diseases data. Additionally, weight (kg), height (m), waist circumference (cm), and blood pressure (mmHg) were measured. Fasting blood samples were obtained from the study subjects.

### 2.1.2. Laboratory Measurements {#sec2.1.2}

The serum levels of glucose and triglycerides were obtained using routine biochemical analysis. High-sensitivity CRP levels were measured by immunenephelometry by the automated system BN-100 (Dade Behring, Germany). The intra- and interassay coefficients of variation of CRP were *\<*4.2% and *\<*5.5%, respectively, and the analytical sensitivity was 0.175 mg/L. The total count of leukocytes was measured in the hematologic system ADVIA-60 (Bayer, USA) the percentage of glycosylated hemoglobin (HbA1c) was performed by the technique of agglutination inhibition (DCA-2000, Bayer, USA).

### 2.1.3. Genotyping {#sec2.1.3}

DNA was extracted from peripheral blood leukocytes using Miller\'s technique \[[@B16]\]. Genotyping of the *CRP*SNPs +1444 C \> T (rs1130864), +1846 G \> A (rs1205), −717 A \> G (rs2794521), and −409 G \> A (rs3093062) was done via PCR-restriction fragment length polymorphism (RFLP) as previously described \[[@B8], [@B9], [@B17], [@B18]\]. The digested fragments were then separated by electrophoresis in 4% agarose gels, followed by ethidium bromide staining and visualized under ultraviolet light. To improve genotyping accuracy, samples with known genotypes were used in each batch as positive controls to evaluate the completeness of PCR product. Details of genotyping method are shown in [Table 1](#tab1){ref-type="table"}.

### 2.1.4. Statistical Analyses {#sec2.1.4}

Quantitative variables were summarized as medians and 25--75 percentiles or geometric means and standard error, and in frequencies for qualitative variables. CHD risk score was stratified by gender, age, blood pressure, cholesterol, triglycerides, and diabetes, a methodology proposed by Wilson et al. \[[@B19]\]. To compare the different factors or SNPs with the study groups, Kruskal-Wallis or chi-square (*χ* ^2^) tests were used. The relationship between CRP and the different variables was determined using the Spearman correlation coefficient. The effect of genotypes and haplotypes of SNPs in the *CRP* gene on CRP levels and BMI was assessed by linear regression models after logarithmic transformation of CRP and BMI. Furthermore, we evaluated multinomial logistic regression models to determine association between SNPs and study groups. Statistical analysis was performed using STATA software (v.11.1). Uncorrected (*P* \< 0.05) or corrected (*P* \< 0.0129) *P* values for the analysis of SNPs based on multiple comparisons correction method proposed by Cheverud \[[@B20]\] were considered statistically significant. Haplotypes were constructed using the genetic data analysis program SNPstats (<http://bioinfo.iconcologia.net/SNPstats>).

3. Results {#sec3}
==========

The clinical and demographic characteristics of the study groups are summarized in [Table 2](#tab2){ref-type="table"}. Subjects with T2D not obese, obese, and T2D obese individuals showed the highest values in different cardiovascular risk factors compared with healthy individuals. Serum CRP was higher in obese individuals (3.6 mg/L) and T2D obese (4.4 mg/L) compared with not obese. Meanwhile, the CHD risk score was higher in individuals with T2D without obesity.

In order to evaluate the risk of CHD, the CRP levels thresholds used were low risk (\<1.0 mg/L), average risk (1.0 to 3.0 mg/L) and high risk (\>3.0 mg/L), based on the criteria of the Centers for Disease Control and the American Heart Association \[[@B21]\]. We found in high risk of CHD 45% of all individuals, higher in T2D obese (74%) and obese (66%) compared with healthy subjects (21.5%), and only 25.1% of all subjects were found in low-risk stratum ([Table 2](#tab2){ref-type="table"}). The CRP blood concentration was significantly correlated with BMI (*P* \< 0.001), systolic blood pressure (*P* = 0.022), glucose (*P* \< 0.001), triglycerides (*P* = 0.022), total leukocyte count (*P* \< 0.001), and the CHD risk score (*P* = 0.038). On the other hand, the increase in the risk score had a significant effect on increasing levels of CRP (*P* = 0.002) adjusted for BMI (data not shown).

The frequency of individuals carrying the TT genotype of SNP rs1130864 was 19.4%, 25.9% for AA of rs1205, 2.2% for GG genotype of rs2794521, and for AA genotype of SNP rs3093062 was not observed in the studied population. The polymorphisms in the healthy group followed the Hardy-Weinberg equilibrium (*P* \> 0.05). The SNP rs1130864 TT genotype was more prevalent in individuals with T2D and obese (*P* = 0.029) ([Table 3](#tab3){ref-type="table"}).

The SNP rs1130864 TT genotype had a marginal effect on increasing levels of CRP and BMI, while the AA genotype of SNP rs1205 influenced the decrease in CRP (*P* = 0.002) by codominant models of inheritance. We also found a significant trend in the increase of the average concentration of CRP between the genotypes of the SNPs rs1130864 and rs3093062 and a decreasing trend in theconcentration of CRP with the SNP rs1205 ([Table 4](#tab4){ref-type="table"}). Additionally, we found an association between the TT genotype of polymorphism rs1130864 with T2D not-obese group (OR = 4.7, 95% CI; 1.7--12.9, *P* = 0.003), the obese group (OR = 4.4, 95% CI; 1.9--10.2, *P* = 0.001), and the group of T2D obese (OR = 5.6, 95% CI; 2.0--15.5, *P* = 0.001), compared with the healthy group, in models adjusted for CHD risk score and region of origin, with a significance level (*α*) of 0.0129. We did not find a significant association between the SNPs with CHD risk score (data not shown).

Haplotype 2 (TGAG) showed a significant association with increased serum levels of CRP and marginally with haplotype 7 (TGGG), compared with the more frequent haplotype (CAAG), while with the increase in BMI it was associated only with haplotype 7 ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

It has been shown that elevated serum CRP is a risk factor for CHD, and there is a relationship between increased serum levels of CRP with various CHD risk factors, particularly diabetes and hypertension \[[@B22], [@B23]\]. On the other hand, it has been reported that several polymorphisms in the *CRP* gene are associated with variation in the concentration of this protein, which is increased with the TT and GG genotypes of the SNPs rs30864 and rs2794521, respectively, and decreased with the AA genotype of rs1205. Also, several alterations have been associated with metabolic syndrome, hypertension, insulin resistance, obesity, and cardiovascular disease, among others \[[@B24], [@B25]\].

Our results are consistent with those reported in different populations of the world where polymorphisms in CRP gene are related with changes in serum levels of CRP \[[@B11], [@B24]\], indicating that their effect on the protein is independent of race/ethnicity. Furthermore, the results confirm the effect of obesity and diabetes on circulating levels of CRP described by other authors. Indicating that in individuals with a low*-*grade chronic systemic inflammation, this environment favors the development of atherosclerosis mediated by a process of endothelial dysfunction \[[@B2], [@B4]\]. We also found that the increase in CHD risk score had a significant effect on increasing levels of CRP; however, this score was not associated with any of the polymorphisms studied. The novelty of the results presented here is the association between the TT genotype of SNP rs1130864 with obesity and T2D and the haplotypes 2 (TGAG) and 7 (TGGG) with increase of CRP and BMI, respectively.

The regulatory effect of IL-6 on CRP gene transcription is a process involving several hepatic transcription factors (C/EBP, HNF, and NF*κ*B). The promoter region of the CRP gene also has binding sites for STAT3 and Rel proteins, where the interaction between these factors gives more stability to the binding C/EBP to DNA and results in maximum gene induction \[[@B26]\]. Furthermore, the 3′UTR region is associated with increased mRNA stability in T allele carriers of SNP rs1130864 and for the G allele of SNP rs1205 and therefore increased expression of CRP \[[@B17]\].

Two regions in chromosomes 1 and 6 with T2D (1q21--q25 and 6q21--q23) have been related by genome scan studies \[[@B27], [@B28]\], where the CRP gene is located on the 1q21--q23 region (<http://www.genenames.org/data/hgnc_data.php?hgnc_id=2367>). Furthermore, an association has been reported of several SNPs in the CRP gene with T2D \[[@B10], [@B23], [@B29]\], suggesting that this may be a candidate gene involved in the development of T2D, a frequent disease in individuals with obesity. We found association between individuals carrying the TT genotype of SNP rs1130864 with obesity or with increased BMI and T2D. This strengthens the hypothesis that CRP may contribute to the development of T2D \[[@B23], [@B29]\]. Eiriksdottir et al. \[[@B30]\] reported a significant interaction between BMI and waist circumference with the AA genotype of SNP rs1205 on CRP levels, indicating that this effect could explain why obesity promotes a more stable mRNA through the G allele, and the strong linkage disequilibrium has been found in different blocks of the CRP gene, as well as in the 3′UTR region in the block formed by the SNPs rs1130864 and rs1205. Casas et al. \[[@B31]\] found significant differences in mean BMI among individuals with TT genotype compared with C allele carriers, meanwhile, Teng et al. \[[@B32]\] found association between the interaction of obesity with SNPs rs2794521 and rs1800947 (*P* = 0.034 and *P* = 0.020, resp.), with increased serum levels of CRP. The SNP rs1130864 TT genotype has been consistently associated with increased serum levels of CRP \[[@B17], [@B24]\] and has been associated with cardiovascular events \[[@B9], [@B33]\].

Several studies have made efforts to determine the effect of haplotypes on certain diseases or phenotypic traits. Different haplotypes in the *CRP* gene have been associated with changes in serum levels of CRP \[[@B11], [@B24]\], with microangiopathic damage, or T2D \[[@B23]\]. We found that haplotypes 2 and 7 were associated with an increase in levels of CRP and IMC, respectively.

5. Conclusion {#sec5}
=============

In summary, our results in the population from Southwestern Mexico indicate that the variation in the CRP gene is associated not only with basal levels of CRP, but also with other disorders such as obesity and T2D, and an association was found with genotype TT of rs1130864 and haplotype 7 (TGGG). Genetic effects on phenotypic traits or diseases are generally small; however, it is possible that a set of polymorphisms together with environmental factors contribute to the development of disease, and obesity to the development of several chronic degenerative diseases modulates the increased risk of these diseases through the genes.

This research was supported by the Mixed Funds of the State of Guerrero of the National Council of Science and Technology and by the Integrated Program for Institutional Strengthening of the Secretary of Public Education (Mexico). The authors wish to thank Dinorah Leyva-Illades (Texas A & M Health Science Center) for revising the English style of this paper.

###### 

PCR primers, products, and restriction enzymes for the genotyping of *CRP* polymorphisms.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  SNP         Forward and reverse primers        PCR product (bp)   Restriction enzyme          Fragments\   Reference                     
                                                                                                (bp)                                       
  ----------- ---------------------------------- ------------------ --------------------------- ------------ --------------- ------------- ------------
  rs1130864   5′-AGCTCGTTAACTATGCTGGGGCA-3′  \   181                *Hp* *yC* *H* ~4~   *III*   CC\          CT\             TT\           \[[@B9]\]
              5′-CTTCTCAGCTCTTGCCTTATGAGT-3′                                                    181          181, 156, 25    156, 25       

                                                                                                                                           

  rs1205      5′-GGAGTGAGACATCTTCTTG-3′  \       227                *Hp* *yC* *H* ~4~   *III*   GG\          GA\             AA\           \[[@B17]\]
              5′-CTTATAGACCTGGGCAGT-3′                                                          130 y 97     227, 130, 97    227           

                                                                                                                                           

  rs2794521   5′-GCCGTCATTTAGTGCCAAC-3′  \       376                *Bstul*                     AA\          AG\             GG\           \[[@B18]\]
              5′-ATGCTCCTCCCAGAGCCATGG-3′                                                       376          376, 199, 177   199, 177      

                                                                                                                                           

  rs3093062   5′-TTTGGGCTAAGTAGGTGTTG-3′  \      116                *Apal I*                    GG\          GA\             AA\           \[[@B8]\]
              5′-AGGGCTCCACTTTGGCTATC-3′                                                        38, 78       116             38, 78, 116   
  -----------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical and demographic characteristics of patients in the study groups.

  ---------------------------------------------------------------------------------------------------------------------------------
  Characteristics                   Healthy\            T2D without obesity\   Obese\              T2D with obesity\   *P* value
  --------------------------------- ------------------- ---------------------- ------------------- ------------------- ------------
  Age (years)                       40 (35--47)         56 (46--67)            43 (38--49)         48 (43--59)         \<0.001^a^

  Gender, *n* (%)                                                                                                       

   Male                             33 (25.4)           30 (32.3)              23 (21.7)           21 (28.8)           0.376^b^

   Female                           97 (74.6)           63 (67.7)              83 (78.3)           52 (71.2)           

  Body mass index (kg/m^2^)         23.6 (22.2--24.6)   24.0 (22.4--24.7)      33.1 (30.8--35.3)   32.0 (30.3--34.3)   \<0.001^a^

  Waist (cm)                        82 (76--87)         86 (82--92)            103 (97--108)       103 (98--108)       \<0.001^a^

  Abdominal obesity, *n* (%)        14 (10.8)           18 (19.4)              97 (91.5)           66 (90.4)           \<0.001^b^

  Systolic blood pressure (mmHg)    107 (95--115)       118 (110--129)         109 (101--123)      112 (103--120)      \<0.001^a^

  Diastolic blood pressure (mmHg)   69 (63--76)         71 (66--79)            72 (67--79)         73 (67--77)         0.006^a^

  Glucose (mg/dL)                   84 (77--89)         174 (120--243)         89 (84--96)         151 (120--222)      \<0.001^a^

  Cholesterol (mg/dL)               197 (167--220)      185 (165--206)         185 (156--218)      184 (161--215)      0.320^a^

  Triglycerides (mg/dL)             141 (99--187)       181 (126--250)         148 (107--187)      191 (142--249)      \<0.001^a^

  Leukocytes (10^3^/*μ*L)           5.8 (5.1--6.2)      6.7 (5.7--6.9)         6.6 (5.7--7.5)      6.4 (5.7--7.0)      \<0.001^a^

  hsCRP (mg/L)\*                    1.2 (0.17)          1.7 (0.33)             3.6 (0.40)          4.4 (0.45)          \<0.001^a^

   \<1                              58 (44.6)           27 (29.0)              11 (10.4)           5 (6.8)             \<0.001^b^

   1--3                             44 (33.9)           36 (38.7)              25 (23.6)           14 (19.2)            

   \>3                              28 (21.5)           30 (32.3)              70 (66.0)           54 (74.0)            

  CHD risk score                    −0.5 (−6, 3)        9 (5, 12)              1 (−5, 4)           6 (4, 9)            \<0.001^a^
  ---------------------------------------------------------------------------------------------------------------------------------

The data indicate median (p25--p75), *n* (%) \*geometric mean (standard error).

^a^Kruskall-Wallis\'s test; ^b^ *χ* ^2^ test.

hsCRP: C-reactive protein high sensitivity. CHD: coronary heart disease.

###### 

Genotypic and allelic frequencies of polymorphisms in the CRP gene by study groups.

  ------------------------------------------------------------------------------------------------------------------
  SNP                  All\         Healthy\       T2D without obesity   Obesity\     T2D with obesity   *P* value
  -------------------- ------------ -------------- --------------------- ------------ ------------------ -----------
  rs1130864                                                                                               

  CC                   108 (26.9)   47 (36.2)      25 (26.9)             20 (18.9)    16 (21.9)          0.029^a^

  CT                   216 (53.7)   68 (52.3)      47 (50.5)             61 (57.5)    40 (54.8)          

  TT                   78 (19.4)    15 (11.5)      21 (22.6)             25 (23.6)    17 (23.3)          

  C                    432 (53.7)   162 (62.3)     97 (52.1)             101 (47.6)   72 (49.3)          

  T                    372 (46.3)   98 (37.7)      89 (47.9)             111 (52.4)   74 (50.7)          

  HWE: *χ* ^2^ (*P*)                1.7 (0.20)                                                           

                                                                                                         

  rs1205                                                                                                  

  GG                   127 (31.6)   37 (28.5)      31 (33.3)             35 (33.0)    24 (32.9)          0.866^a^

  GA                   171 (42.5)   55 (42.3)      37 (39.8)             45 (42.5)    34 (46.6)          

  AA                   104 (25.9)   38 (29.2)      25 (26.9)             26 (24.5)    15 (20.6)          

  G                    425 (52.9)   129 (49.6)     99 (53.2)             115 (54.3)   82 (56.2)          

  A                    379 (47.1)   131 (50.4)     87 (46.8)             97 (45.8)    64 (43.8)          

  HWE: *χ* ^2^ (*P*)                3.0 (0.08)                                                           

                                                                                                         

  rs2794521                                                                                               

  AA                   314 (78.1)   111 (85.4)     68 (73.1)             81 (76.4)    54 (74.0)          0.281^b^

  AG                   79 (19.7)    17 (13.1)      22 (23.7)             23 (21.7)    17 (23.3)          

  GG                   9 (2.2)      2 (1.5)        3 (3.2)               2 (1.9)      2 (2.7)            

  A                    707 (87.9)   239 (91.9)     158 (85.0)            185 (87.3)   125 (85.6)         

  G                    97 (12.1)    21 (8.1)       28 (15.0)             27 (12.7)    21 (14.4)          

  HWE: *χ* ^2^ (*P*)                1.9 (0.174)                                                          

                                                                                                         

  rs3093062                                                                                               

  GG                   378 (94.0)   127 (97.7)     86 (92.5)             98 (92.5)    67 (91.8)          0.137^b^

  GA                   24 (6.0)     3 (2.3)        7 (7.5)               8 (7.5)      6 (8.2)            

  G                    780 (97.0)   257 (98.9)     179 (96.2)            204 (96.2)   140 (95.9)         

  A                    24 (3.0)     3 (1.1)        7 (3.8)               8 (3.8)      6 (4.1)            

  HWE: *χ* ^2^ (*P*)                0.02 (0.894)                                                         
  ------------------------------------------------------------------------------------------------------------------

The data indicate *n* (%). HWE: Hardy-Weinberg equilibrium.

^a^ *χ* ^2^ test; ^b^Fisher\'s exact test.

###### 

Effect of the SNPs on hsCRP levels or BMI.

  SNP         CRP (mg/L)       Log CRP (mg/L)      BMI (kg/m^2^)   Log BMI (kg/m^2^)                        
  ----------- ---------------- ------------------- --------------- ------------------- -------------------- -------
  rs1130864                                                                                                  
  CC          1.7 (1.4--2.1)   Reference                           26.2 (25.3--27.1)   Reference             
  CT          2.3 (2.0--2.6)   0.2 (0.05, 0.4)     0.128           27.4 (26.7--28.1)   0.04 (−0.02, 0.1)    0.065
  TT          2.9 (2.2--3.9)   0.4 (0.1, 0.7)      0.015           28.2 (26.8--29.7)   0.1 (0.01, 0.1)      0.016
  *P* trend   0.001                                                0.012                                     
  CT + TT     2.4 (2.1--2.8)   0.2 (0.1, 0.6)      0.045           27.6 (27.0--28.3)   0.05 (0.01, 0.1)     0.024
                                                                                                            
  rs1205                                                                                                     
  GG          2.5 (2.0--3.0)   Reference                           27.5 (27.0--29.4)   Reference             
  GA          2.6 (2.2--3.0)   0.1 (−0.2, 0.3)     0.423           27.4 (26.6--28.2)   −0.01 (−0.1, 0.04)   0.871
  AA          1.5 (1.2--1.9)   −0.4 (−0.7, −0.2)   0.002           26.6 (25.7--27.6)   −0.03 (−0.1, 0.02)   0.197
  *P* trend   0.001                                                0.220                                     
  GA + AA     2.1 (1.8--2.4)   −0.1 (−0.3, −0.1)   0.334           27.1 (26.5--27.7)   −0.02 (−0.1, 0.02)   0.477
                                                                                                            
  rs2794521                                                                                                  
  AA          2.1 (1.9--2.4)   Reference                           27.0 (26.4--27.6)   Reference             
  AG          2.7 (2.1--3.4)   0.1 (−0.1, 0.4)     0.317           28.1 (26.8--29.4)   0.04 (−0.01, 0.1)    0.105
  GG          2.1 (0.7--6.0)   −0.1 (−0.8, 0.4)    0.747           28.2 (24.2--32.9)   0.04 (−0.1, 0.2)     0.501
  *P* trend   0.164                                                0.109                                     
  AG + GG     2.6 (2.1--3.3)   0.1 (−0.1, 0.3)     0.398           28.1 (26.9--29.4)   0.04 (−0.01, 0.08)   0.087
                                                                                                            
  rs3093062                                                                                                  
  GG          2.1 (1.9--2.4)   Reference                           27.1 (26.6--27.7)   Reference             
  GA          3.7 (2.4--5.9)   0.3 (−0.1, 0.8)     0.108           29.4 (26.6--32.3)   0.1 (−0.01, 0.2)     0.060
  *P* trend   0.020                                                0.060                                     

^a^Models adjusted by risk score of coronary heart disease, body mass index, and place of origin.

^b^Models adjusted by risk score of coronary heart disease and place of origin. GM: geometric mean.

^c^Uncorrected *P* values.

###### 

Association of haplotypes in CRP gene with circulating levels of CRP and body mass index.

  Haplotype   SNP       Log CRP (mg/L)   Log BMI (kg/m^2^)                                                            
  ----------- ----- --- ---------------- ------------------- -------- ------------------ ------- -------------------- ---------
  1           C     A   A                G                   0.2934   Ref                        Ref                   
  2           T     G   A                G                   0.2818   0.3 (0.1, 0.5)     0.005   0.04 (0, 0.1)        0.059
  3           C     G   A                G                   0.1523   0.2 (−0.01, 0.5)   0.057   0.01 (−0.04, 0.06)   0.57
  4           T     A   A                G                   0.127    0.2 (−0.1, 0.4)    0.27    0.04 (−0.02, 0.1)    0.17
  5           C     G   G                G                   0.0403   0.1 (−0.4, 0.5)    0.72    −0.03 (−0.1, 0.1)    0.46
  6           C     A   G                G                   0.0389   0.1 (−0.3, 0.6)    0.59    0.07 (−0.03, 0.2)    0.16
  7           T     G   G                G                   0.0291   0.7 (0.2, 1.2)     0.01    0.2 (0.1, 0.3)       \<0.001
  8           C     G   A                A                   0.0101   0.7 (−0.04--1.5)   0.063   0.2 (0, 0.3)         0.049
  Rare                                                       0.027    0.6 (0.1, 1.1)     0.015   0.1 (−0.1, 0.2)      0.29

^a^Models adjusted by risk score of coronary heart disease, body mass index, and place of origin.

^b^Models adjusted by risk score of coronary heart disease and place of origin.

^c^Uncorrected *P* values.

[^1]: Academic Editor: Åke Lernmark
